Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
- Approval of a new patent strengthens Pluri's position in the agtech sector and showcases its innovative capabilities.
- The patented technology allows for the efficient cultivation of plant cells, particularly for sustainable agriculture and healthcare solutions.
- Pluri's 3D cell expansion technology can produce high-quality coffee with significantly reduced water and growing area requirements, addressing environmental sustainability.
- The global cellular agriculture market's significant growth potential positions Pluri's patented technology as a transformative force within the industry.
- Pluri's CEO emphasizes the strategic importance of the patent in scaling the production of cell-based products and exploring diverse market opportunities.
- The patent enhances Pluri's competitive edge in sustainable agriculture and underscores its commitment to providing solutions for global challenges.
- Pluri's robust IP portfolio, with over 140 active and granted patents, highlights its pioneering role in the agtech sector.
- None.
The approval of Pluri Inc.'s new patent for a 3D Cultivation of Plant Cells system is a significant development in the agricultural technology (agtech) sector. This technology, which allows for efficient cultivation of plant cells, has the potential to revolutionize sustainable agriculture practices. The immediate application of this technology in producing cell-based coffee, which requires substantially less water and growing area, could lead to a considerable reduction in the environmental impact of coffee production.
From a market perspective, the integration of this technology into Pluri's business model could open up new revenue streams and partnerships, especially given the projected growth of the cellular agriculture market from $133 billion in 2021 to $515 billion by 2030. This patent could provide Pluri with a competitive edge, allowing it to capitalize on the growing demand for sustainable agricultural solutions.
The environmental benefits of Pluri's 3D cell expansion technology are noteworthy. The technology's ability to produce high-quality coffee with 98% less water and 95% less growing area addresses two major environmental concerns: water scarcity and land use. In the context of climate change and increasing pressure on natural resources, such innovations are critical. Additionally, the potential application in preserving threatened medical plants could have far-reaching implications for biodiversity conservation and the sustainability of natural medicine sources.
Investors will likely scrutinize the financial implications of Pluri's patent. The company's robust IP portfolio, now exceeding 140 active and granted patents, is indicative of its commitment to innovation and could be a key driver of investor confidence. The potential market opportunities in food, beverages, medicine and ingredients present a diverse portfolio for growth. It will be important to monitor the company's ability to scale production and secure partnerships that leverage this patented technology, as these factors will be pivotal in determining the long-term financial success and stock performance of Pluri Inc.
Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product
HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape. The patent titled “A System for 3D Cultivation of Plant Cells and Methods of Use” represents a major breakthrough in Pluri's proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions.
An immediate application for the patent is PluriAgtech’s sustainable cell-based coffee. The 3D cell expansion technology can produce high-quality coffee with
The global cellular agriculture market was valued at
With over 140 active and granted patents, Pluri's robust IP portfolio is a testament to its pioneering role in the agtech industry. This patent, secured from the Israel Patent Office, further enhances Pluri's competitive positioning through innovative contributions to sustainable agriculture and beyond.
“We believe this patent positions Pluri as a leader in cell expansion technology for the agtech industry,” stated Mr. Yanay. “PluriAgtech’s patented technology can be used for a wide range of plant cell products like food and beverages, medicine, ingredients and more. We see many opportunities in the agtech space, where Pluri is on the forefront of providing sustainable solutions for humanity’s greatest challenges both through our own proprietary products and in conjunction with potential partners.”
About Pluri Inc.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services. To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its belief that its patent represents a major breakthrough in Pluri's proprietary 3D bioreactor technology, the potential uses and benefits of its technologies and products, the growth projections for the global cellular agriculture market, that its newly patented technology is a potentially transformative force within its industry, its belief that cell expansion has the potential to become a major driver and future pillar of agtech, and the potential opportunities in the agtech space. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.
Media Contacts
Investors: investor.relations@pluri-biotech.com / Jennifer Zimmons at Jen@quantum-corp.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com / Jessica Daitch at Jessica@quantum-corp.com
FAQ
What is the title of the new patent approved by Pluri Inc.?
What is the immediate application of the newly approved patent by Pluri Inc.?
How much water usage reduction is achieved by Pluri's 3D cell expansion technology?
What percentage of growing area reduction is enabled by Pluri's 3D cell expansion technology?
What is the projected value of the global cellular agriculture market by 2030?
